Publications by authors named "Zengerling F"
Introduction: Adjuvant pembrolizumab versus placebo significantly improved disease-free survival (DFS) in renal cell carcinoma (RCC) patients at high risk of recurrence following nephrectomy in KEYNOTE-564 trial (NCT03142334). The objective of this study was to evaluate efficacy and safety of adjuvant pembrolizumab in a real-world setting.
Methods: In this multicenter retrospective study, RCC patients receiving adjuvant pembrolizumab between 01/22 and 10/23 at seven tertiary referral centers were included.
Urothelial carcinoma (UC) of the urinary bladder has significant challenges in treatment due to its diverse genetic landscape and variable response to systemic therapy. In recent years, patient-derived organoids (PDOs) emerged as a novel tool to model primary tumors with higher resemblance than conventional 2D cell culture approaches. However, the potential of organoids to predict therapy response in a clinical setting remains to be evaluated.
View Article and Find Full Text PDFIntroduction: To assess gender-specific differences in recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) among patients with intermediate or high-risk non-muscle-invasive bladder cancer (NMIBC) receiving BCG was the primary aim of this systematic review and meta-analysis.
Methods: In July 2023, we performed a literature search using MEDLINE, Embase, and the Cochrane Library. This study was prospectively registered at PROSPERO (CRD 2023443269).
Background: We have previously identified an unsuspected role for GJB3 showing that the deficiency of this connexin protein induces aneuploidy in human and murine cells and accelerates cell transformation as well as tumor formation in xenograft models. The molecular mechanisms by which loss of GJB3 leads to aneuploidy and cancer initiation and progression remain unsolved.
Methods: GJB3 expression levels were determined by RT-qPCR and Western blot.
Article Synopsis
- Atezolizumab was assessed for its safety in a diverse group of patients with pretreated urinary tract carcinoma (UTC) in the SAUL study, which included those typically excluded from clinical trials.
- The study involved 1004 patients and found that 68 patients continued treatment for over 4 years, with 16% experiencing serious treatment-related adverse events.
- Long-term results show a median overall survival of 8.6 months, with 14% of patients surviving more than 4 years, indicating the drug's potential benefits in real-world settings with complex patient profiles.
Introduction: The aim was to compare treatment outcomes of clear cell metastatic renal cell carcinoma (ccmRCC) versus non-ccmRCC (nccmRCC) patients who received first-line immune combination therapies.
Materials And Methods: Within our retrospective multi-institutional consecutive database of eight tertiary-care centers, we identified mRCC patients treated with first-line immune combination therapies between 11/2017 and 12/2022. Using log-rank analysis and multivariable Cox regression, we tested for differences in overall survival (OS) and progression-free survival (PFS) of nccmRCC versus ccmRCC patients.
Importance: Studies with nivolumab, an approved therapy for metastatic urothelial carcinoma (mUC) after platinum-based chemotherapy, demonstrate improved outcomes with added high-dose ipilimumab.
Objective: To assess efficacy and safety of a tailored approach using nivolumab + ipilimumab as an immunotherapeutic boost for mUC.
Design, Setting, And Participants: In this phase 2 nonrandomized trial, patients with mUC composed 2 cohorts.
Objective: To investigate and compare the performance of urinary cytology and the Xpert BC Monitor test in the detection of bladder cancer in various clinically significant patient cohorts, including patients with carcinoma in situ (CIS), in a prospective multicentre setting, aiming to identify potential applications in clinical practice.
Patients And Methods: A total of 756 patients scheduled for transurethral resection of bladder tumour (TURBT) were prospectively screened between July 2018 and December 2020 at six German University Centres. Central urinary cytology and Xpert BC Monitor tests were performed prior to TURBT.
Purpose: The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. is located on chromosome 1q23.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on predicting lymph node metastasis (LNM) in testicular cancer to improve treatment decisions and prognosis, using a sample of 91 early-stage patients.
- Researchers developed predictive models by combining clinical risk factors such as age, tumor markers, histotype, and BMI with lymph node radiomics features using various machine learning methods.
- The Random Forest model showed the best predictive performance (AUC of 0.95), indicating that integrating machine learning with radiomics and clinical factors can enhance precision in oncology for testicular cancer treatment.
Article Synopsis
- * Out of 258 patients monitored over 18 months, the M371 test achieved 100% sensitivity and 96.3% specificity for relapse detection, with some ability to detect relapses earlier.
- * While the M371 test shows promise for routine use in monitoring relapses, postoperative levels of M371 did not predict future relapses, and the time advantage for earlier detection was not significant.
Article Synopsis
- The study explores the predictive and prognostic value of C-reactive protein (CRP) kinetics in patients with metastatic renal carcinoma undergoing immunotherapy.
- Analysis involved categorizing patients into groups based on two definitions (Fukuda and Ishihara), allowing comparisons of treatment outcomes like progression-free survival (PFS) and overall survival (OS).
- Results indicated that specific CRP responses correlated with improved PFS and OS, suggesting CRP kinetics could be useful in predicting therapy response, but further investigation into measurement practices is necessary.
Article Synopsis
- Scientists found that a protein called ORP3 helps control cell numbers and can stop cancer from forming.
- In bladder cancer, ORP3 is less active as the cancer gets worse, and when it’s missing, cancer becomes more likely.
- ORP3 helps keep cells stable and affects their movement, showing it plays a big part in stopping cancer from spreading.
To determine whether Xpert bladder cancer monitor, a noninvasive PCR-based biomarker test, can predict the need for 2nd transurethral resection of the bladder (TURB) better than clinical assessment. Patients scheduled for TURB were prospectively screened. After initial TURB, patients were assigned to 2nd TURB or follow-up cystoscopy at 3 months (FU) by clinicians' discretion.
View Article and Find Full Text PDFProstate-specific membrane antigen (PSMA) hybrid imaging is a promising new technique gaining importance in the field of prostate cancer (PCa) diagnosis and treatment planning. By combining PSMA radioligands and computed tomography (CT) or magnetic resonance imaging (MRI), PSMA hybrid imaging opens up new diagnostic opportunities. PSMA-PET/CT (PET: positron-emission tomography) is already well established in high-risk PCa for primary staging and tumor localization when biochemical recurrence occurs.
View Article and Find Full Text PDFBackground: Treatment options for patients with urothelial cancer (UC) refractory to platinum and immunotherapy are limited and survival is short. Enfortumab vedotin (EV) is a monoclonal anti-NECTIN4 antibody conjugated to monomethyl auristatin. It was recently approved because of superior survival in comparison to standard-of-care (SOC) chemotherapy.
View Article and Find Full Text PDFCastration resistant prostate cancer (CRPC) is characterized by an aggressive biological behavior with a relatively short survival time, especially in progressive tumors pretreated with new hormonal agents and taxane chemotherapy. [177Lu]-Lutetium-PSMA (Lu-PSMA) treatment has proven efficacy in these patients. However, around 30% of the CRPC patients do not benefit from Lu-PSMA treatment, and little is known about predictive factors for treatment success if Lu-PSMA is offered in an individualized approach based on clinical and laboratory features.
View Article and Find Full Text PDFArticle Synopsis
- Geriatric co-management enhances care for older adults but faces challenges due to limited resources, which the SURGE-Ahead project aims to address through digital solutions and AI support.
- The project will develop a user-friendly digital application that provides evidence-based recommendations and AI-driven continuity of care suggestions, following a structured research framework.
- Data will be collected from multiple surgical departments to train AI, evaluate user needs, and improve the application, with usability testing to ensure it meets the needs of medical professionals in real-world settings.
Article Synopsis
- Immune checkpoint inhibitors are the go-to first-line treatments for metastatic renal cell carcinoma, but effective options after disease progression remain unclear; this study investigates adding atezolizumab to cabozantinib for better outcomes.
- The CONTACT-03 phase 3 trial involved 522 patients assigned to receive either the combination treatment or cabozantinib alone, with the primary goals of measuring progression-free and overall survival.
- Results from the trial, which included a diverse international patient population, are still being analyzed, with a median follow-up period of 15.2 months recorded as of January 2023.
Purpose: To analyze gender-specific differences in survival parameters in advanced or metastatic urothelial cancer patients undergoing immune checkpoint inhibition.
Methods: The primary aim of this systematic review and meta-analysis was to evaluate gender-specific differences in disease-free (DFS), progression-free (PFS), cancer-specific survival (CSS), event-free survival (EFS), overall survival (OS) and objective response rate (ORR). The sources MEDLINE, Embase and Cochrane Library were systematically searched from January 2010 to June 2022.